Atrium Therapeutics Advances Precision Cardiology with New Trial

The company reported a net loss of $20.2 million for the second quarter of 2026, as research and development expenses climbed to $15.3 million. These costs reflect the intensive preparations for the Corventis trial and ongoing efforts to refine their RNA-based delivery platform. Despite the quarterly loss, the firm maintains a strong liquidity position, holding $263.9 million in cash and short-term investments as of June 30, which management expects will sustain operations through mid-2028.

Operational momentum was bolstered by a $15 million milestone payment from Bristol Myers Squibb, earned in August through their global cardiovascular collaboration. The Corventis trial will enroll approximately 37 participants to evaluate the safety and efficacy of ATR 1072, with the first patient expected to be enrolled by the end of this year. Looking beyond this program, the company plans to file an IND application for its second candidate, ATR 1086, in 2027.